We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY - Free Report) announced that the European Commission (EC) has approved Povofortay (povorcitinib) 45 mg and 75 mg for treating eligible adults with moderate to severe hidradenitis suppurativa (HS).
The approval marks an important milestone for the company, as Povofortay is expected to be a key growth driver.
Povofortay is the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS.
HS is a chronic inflammatory skin disease marked by painful nodules, abscesses and draining tunnels, which can cause irreversible tissue damage and scarring. The debilitating condition can significantly impair patients' quality of life.
Shares of Incyte have rallied 21.7% year to date compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
More on INCY’s HS Drug Approval
The approval is based on results from the late-stage STOP-HS1 and STOP-HS2 studies, which evaluated the drug's safety and efficacy in patients with moderate to severe HS.
Both studies met their primary endpoint, with significantly more patients receiving either dose of Povofortay (45 mg or 75 mg) achieving Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 12 compared with placebo. Consistent efficacy was also observed among patients previously treated with anti-TNF therapy, the population covered by the EU indication.
The treatment demonstrated durable efficacy through week 54, with up to 71.4% of patients achieving HiSCR50. Furthermore, up to 57% and 29% of patients achieved HiSCR75 and HiSCR100, respectively. Improvements were also observed in skin pain, fatigue and quality of life.
Povofortay's safety profile over 54 weeks was consistent with previously reported data, with both doses well tolerated and no new or unexpected safety signals. The most common treatment-emergent adverse events were acne, nasopharyngitis and upper respiratory tract infections, with most events being mild or moderate.
The approval of Povofortay broadens Incyte's portfolio. Meanwhile, the FDA is reviewing the company's new drug application for povorcitinib in moderate to severe HS. The application is supported by the STOP-HS1 and STOP-HS2 results, with U.S. approval and launch anticipated in the first quarter of 2027.
INCY’s Efforts to Expand Portfolio
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
At present, lead drug Jakafi accounts for the lion’s share of revenues.
The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.
Encouraging uptake of Opzelura, Monjuvi, Niktimvo and Zynyz contributes to its top-line growth.
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
Incyte's pipeline provides additional opportunities to drive long-term growth beyond 2029. Key programs include a CALR-targeted monoclonal antibody for myeloproliferative neoplasms, a novel Protein S modulator for von Willebrand disease, a KRAS G12D inhibitor for pancreatic and colorectal cancers, and a TGFβR2×PD-1 bispecific antibody for colorectal cancer. These candidates offer multiple potential growth avenues, with upcoming clinical, regulatory and commercial milestones serving as important catalysts for the company.
Over the past 60 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.13 to $7.39, while estimates for 2027 have increased from $5.34 to $6.84 during the same time. COLL shares have gained 10.5% in a month.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.
Image: Bigstock
INCY Wins European Commission Nod For Skin Disease Drug
Key Takeaways
Incyte (INCY - Free Report) announced that the European Commission (EC) has approved Povofortay (povorcitinib) 45 mg and 75 mg for treating eligible adults with moderate to severe hidradenitis suppurativa (HS).
The approval marks an important milestone for the company, as Povofortay is expected to be a key growth driver.
Povofortay is the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS.
HS is a chronic inflammatory skin disease marked by painful nodules, abscesses and draining tunnels, which can cause irreversible tissue damage and scarring. The debilitating condition can significantly impair patients' quality of life.
Shares of Incyte have rallied 21.7% year to date compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
More on INCY’s HS Drug Approval
The approval is based on results from the late-stage STOP-HS1 and STOP-HS2 studies, which evaluated the drug's safety and efficacy in patients with moderate to severe HS.
Both studies met their primary endpoint, with significantly more patients receiving either dose of Povofortay (45 mg or 75 mg) achieving Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 12 compared with placebo. Consistent efficacy was also observed among patients previously treated with anti-TNF therapy, the population covered by the EU indication.
The treatment demonstrated durable efficacy through week 54, with up to 71.4% of patients achieving HiSCR50. Furthermore, up to 57% and 29% of patients achieved HiSCR75 and HiSCR100, respectively. Improvements were also observed in skin pain, fatigue and quality of life.
Povofortay's safety profile over 54 weeks was consistent with previously reported data, with both doses well tolerated and no new or unexpected safety signals. The most common treatment-emergent adverse events were acne, nasopharyngitis and upper respiratory tract infections, with most events being mild or moderate.
The approval of Povofortay broadens Incyte's portfolio. Meanwhile, the FDA is reviewing the company's new drug application for povorcitinib in moderate to severe HS. The application is supported by the STOP-HS1 and STOP-HS2 results, with U.S. approval and launch anticipated in the first quarter of 2027.
INCY’s Efforts to Expand Portfolio
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
At present, lead drug Jakafi accounts for the lion’s share of revenues.
The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
Jakafi is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.
Encouraging uptake of Opzelura, Monjuvi, Niktimvo and Zynyz contributes to its top-line growth.
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
Incyte's pipeline provides additional opportunities to drive long-term growth beyond 2029. Key programs include a CALR-targeted monoclonal antibody for myeloproliferative neoplasms, a novel Protein S modulator for von Willebrand disease, a KRAS G12D inhibitor for pancreatic and colorectal cancers, and a TGFβR2×PD-1 bispecific antibody for colorectal cancer. These candidates offer multiple potential growth avenues, with upcoming clinical, regulatory and commercial milestones serving as important catalysts for the company.
INCY’s Zacks Rank & A Stock to Consider
INCY currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Collegium Pharmaceutical (COLL - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.13 to $7.39, while estimates for 2027 have increased from $5.34 to $6.84 during the same time. COLL shares have gained 10.5% in a month.
Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.